Supernus Pharmaceuticals (NASDAQ:SUPN) Cut to Buy at StockNews.com

StockNews.com downgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN) from a strong-buy rating to a buy rating in a research report sent to investors on Monday.

Separately, Cantor Fitzgerald restated a “neutral” rating and set a $36.00 price target on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 26th.

Supernus Pharmaceuticals Stock Down 2.2 %

Shares of SUPN opened at $32.33 on Monday. The firm has a market cap of $1.80 billion, a PE ratio of 30.22 and a beta of 0.83. The company’s fifty day moving average is $35.37 and its two-hundred day moving average is $35.03. Supernus Pharmaceuticals has a fifty-two week low of $25.53 and a fifty-two week high of $40.28.

Insider Activity

In other news, VP Padmanabh P. Bhatt sold 9,477 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $39.70, for a total transaction of $376,236.90. Following the sale, the vice president now owns 10,149 shares in the company, valued at $402,915.30. This trade represents a 48.29 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Jonathan Rubin sold 927 shares of the business’s stock in a transaction on Friday, February 21st. The stock was sold at an average price of $39.15, for a total transaction of $36,292.05. Following the transaction, the senior vice president now directly owns 7,853 shares in the company, valued at approximately $307,444.95. The trade was a 10.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 11,104 shares of company stock valued at $440,263. Company insiders own 9.30% of the company’s stock.

Hedge Funds Weigh In On Supernus Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in SUPN. Woodline Partners LP increased its position in shares of Supernus Pharmaceuticals by 124.8% during the fourth quarter. Woodline Partners LP now owns 423,828 shares of the specialty pharmaceutical company’s stock worth $15,326,000 after acquiring an additional 235,257 shares during the last quarter. BNP Paribas Financial Markets increased its holdings in Supernus Pharmaceuticals by 248.0% during the 4th quarter. BNP Paribas Financial Markets now owns 292,629 shares of the specialty pharmaceutical company’s stock worth $10,581,000 after purchasing an additional 208,552 shares during the last quarter. Raymond James Financial Inc. acquired a new position in shares of Supernus Pharmaceuticals in the 4th quarter valued at approximately $6,847,000. Great Lakes Advisors LLC purchased a new position in shares of Supernus Pharmaceuticals during the 4th quarter valued at approximately $6,131,000. Finally, D. E. Shaw & Co. Inc. grew its position in shares of Supernus Pharmaceuticals by 33.5% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 545,658 shares of the specialty pharmaceutical company’s stock worth $19,731,000 after buying an additional 136,870 shares in the last quarter.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.